Loading
Life sciences · Journal article
Avicenna Journal of Medical Biotechnology · October 7, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background: Hepatocellular Carcinoma (HCC) remains a leading cause of cancer-related mortality worldwide, and developing tumor-selective therapies with minimal off-target toxicity is a major challenge. Alpha-fetoprotein (AFP), which is highly expressed in HCC but absent in most normal adult hepatocytes, is a promising target for selective gene therapy. Apoptin, a viral protein, induces apoptosis preferentially in malignant cells. Methods: An AFP promoter-driven Apoptin expression construct was generated using the pAdenoVator-IRES-GFP vector and transiently transfected into HepG2 cells. Promoter specificity was evaluated in AFP-negative HeLa and LNCaP cells. Transfection efficiency was assessed by GFP fluorescence microscopy. Cell viability was measured by MTT assay, Apoptin mRNA expression by RT-qPCR, and apoptosis by Annexin V/7-AAD flow cytometry. Experiments were performed in triplicate. Results: GFP fluorescence was visibly stronger in HepG2 cells than in HeLa or LNCaP cells on qualitative microscopic examination, consistent with AFP promoter selectivity. AFP promoter-driven Apoptin expression significantly reduced HepG2 cell viability to 50.2%±4.3% of control levels (p=0.0317, n=3 independent experiments). RT-qPCR showed a significant increase in Apoptin mRNA expression in transfected HepG2 cells. Flow cytometry showed a significant increase in apoptosis, with approximately 20% more Annexin V-positive cells than controls (p=0.0286, n=3 independent experiments). Conclusion: AFP promoter-driven Apoptin expression selectively induced apoptosis and reduced viability in HCC cells in vitro. These findings highlight the potential of AFP promoter-based Apoptin gene therapy as a tumor-selective therapeutic approach for HCC and support further evaluation in preclinical models.